Cytopia targeting protein kinases
Wednesday, 18 June, 2008
Melbourne biotech Cytopia (ASX: CYT) is to present data from its study on FMS inhibitors at the Protein Kinase Targets oncology conference in Boston next week.
This will be the first formal disclosure of data from the study, in which a series of compounds discovered by Cytopia were found to inhibit the function of microphages, key cells in the immune system which also mediate inflammatory reactions.
One of the potential applications of the compounds is as a treatment of rheumatoid arthritis. The compounds are also showing potential as an inhibitor of the cells that cause bone osteolysis in advanced cancer sufferers.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
